EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Substance use outcomes from the Child/Adolescent Anxiety Multimodal Extended Long‐term Study (CAMELS)

Jonathan Rabner iD, Thomas M Olino iD, Anne Marie Albano, Courtney P Keeton, Dara Sakolsky, Boris Birmaher, John Piacentini, Tara S Peris, Scott N Compton, Elizabeth Gosch, Golda S Ginsburg, Elizabeth L Pinney und 1 weitere

Journal of Child Psychology and Psychiatry · 2024

DOI: 10.1111/jcpp.13926 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Child Psychology and Psychiatry, 2024. Verfasst von Jonathan Rabner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology and Neuorscience, Temple University, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Cognitive Behavioral Therapy, Substance-Related Disorders, Anxiety Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: NIMH NIH HHS, Civic Foundation, National Institute of Mental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Substance use problems and anxiety disorders are both highly prevalent and frequently cooccur in youth. The present study examined the benefits of successful anxiety treatment at 3–12 years after treatment completion on substance use outcomes (i.e. diagnoses and lifetime expected use).

Methods

The sample was from the Child/Adolescent Anxiety Multimodal Extended Long‐term Study (CAMELS), a naturalistic follow‐up study to the Child/Adolescent Anxiety Multimodal Study (CAMS) which randomized youth to cognitive behavioral therapy (CBT; Coping cat ), medication (sertraline), their combination, or pill placebo. The first CAMELS visit occurred an average of 6.5 years following CAMS randomization. Participants were 319 youth (65.4% of the CAMS sample), aged 7–17 years at CAMS baseline assessment with a mean age of 17.6 years (range: 11–26 years) at the time of the first CAMELS follow‐up. Substance use outcomes included diagnoses as well as lifetime substance use (i.e. alcohol and tobacco use).

Results

Eleven of 319 (3.4%) CAMELS participants were diagnosed with a substance use disorder at the initial follow‐up visit. When compared to the population lifetime rate of 11.4%, the rate of diagnoses in the posttreated sample was significantly lower. Additionally, rates of lifetime alcohol use were lower than population rates at the initial and final follow‐up visits. Rates of lifetime tobacco use were similarly lower than lifetime population rates at the initial visit (driven by significantly lower rates in the CBT treatment condition), but higher by the final visit. Furthermore, treatment remission (but not treatment response) was associated with a lower rate of substance use diagnoses at the initial follow‐up visit, although rates of lifetime alcohol and tobacco use did not differ by treatment outcome.

Conclusions

Anxiety treatments confer a beneficial impact on problematic substance use (i.e. diagnoses) as well as on expected substance use (i.e. alcohol and tobacco use) for on average, a period of 6.5 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive Behavioral TherapySubstance-Related DisordersAnxiety DisordersHumansAdolescentChildMaleFemaleCombined Modality TherapyFollow-Up StudiesSertralineYoung AdultAdultComorbidityOutcome Assessment, Health Care

Stichwörter der Autor:innen

Anxiety disorderscognitive behavioral therapysecondary preventionsubstance useyouth

Substanzen

Sertraline

Autor:innen und Institutionen

  • Department of Psychology and Neuorscience, Temple University, Philadelphia, PA, USA.
  • Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, USA.
  • Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
  • Western Psychiatric Institute & Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles School of Medicine, Los Angeles, CA, USA.

ORCID-Profile: Jonathan Rabner, Thomas M Olino

Förderung

  • NIMH NIH HHS
  • Civic Foundation
  • National Institute of Mental Health

Zitieren

APA

Rabner, J., Olino, T. M., Albano, A. M., Keeton, C. P., Sakolsky, D., Birmaher, B., Piacentini, J., Peris, T. S., Compton, S. N., Gosch, E., Ginsburg, G. S., Pinney, E. L., & Kendall, P. C. (2024). Substance use outcomes from the Child/Adolescent Anxiety Multimodal Extended Long‐term Study (CAMELS). Journal of Child Psychology and Psychiatry. https://doi.org/10.1111/jcpp.13926

Vancouver

Rabner J, Olino TM, Albano AM, Keeton CP, Sakolsky D, Birmaher B, et al. Substance use outcomes from the Child/Adolescent Anxiety Multimodal Extended Long‐term Study (CAMELS). Journal of Child Psychology and Psychiatry. 2024. doi:10.1111/jcpp.13926

BibTeX
@article{Rabner2024,
  author = {Rabner, Jonathan and Olino, Thomas M and Albano, Anne Marie and Keeton, Courtney P and Sakolsky, Dara and Birmaher, Boris and Piacentini, John and Peris, Tara S and Compton, Scott N and Gosch, Elizabeth and Ginsburg, Golda S and Pinney, Elizabeth L and Kendall, Philip C},
  title = {Substance use outcomes from the Child/Adolescent Anxiety Multimodal Extended Long‐term Study (CAMELS)},
  journal = {Journal of Child Psychology and Psychiatry},
  year = {2024},
  doi = {10.1111/jcpp.13926}
}
Kostenlos starten →